ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
13 announcements with these filters
Hester Biosciences Limited received shareholder approval to reclassify Mr. Ravin Gandhi and Ms. Bela Gandhi from the 'Promoter' category to the 'Public' category.
Hester Biosciences Limited shareholders approved the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public' category via postal ballot.
Hester Biosciences Ltd received an upgrade in its long-term and short-term bank facility credit ratings from CARE Ratings.
Hester Biosciences is conducting a postal ballot to seek shareholder approval for the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public'.
Hester Biosciences Limited has launched a dedicated interactive digital microsite for its 39th Annual Report for FY 2025-26 to enhance stakeholder accessibility and engagement.
Hester Biosciences delivered strong standalone Q1 growth with revenues up 14% and profit up 88%. Consolidated profit surged 459% due to an INR 853.49 million exceptional gain from a loan amendment.
Hester Biosciences reported Q1 FY27 results, with standalone revenue up 14% to ₹72.60 Crore and profit growing 88% to ₹14.71 Crore.
Hester Biosciences Ltd reported revenue from operations of ₹77.2 Cr (-8.2% YoY) and net profit of ₹96.7 Cr (+459.0% YoY) for Q1 FY27.
Hester Biosciences received no-objection letters from NSE and BSE for the re-classification of Mr. Ravin Gandhi and Ms. Bela Gandhi from Promoter to Public category.
Hester Biosciences has scheduled a board meeting for 30 July 2026 to consider unaudited standalone and consolidated financial results for the quarter ended 30 June 2026.
Hester Biosciences Limited successfully concluded its 39th Annual General Meeting. Shareholders approved all resolutions, including the adoption of financial statements and the declaration of dividend.
Hester Biosciences exited its 11% stake in Texas Lifesciences for Rs. 2.3 Crore. The company now holds nil investment in the entity.
Hester Biosciences corrected its AGM notice, updating the Executive Director’s gross salary to INR 10 lakh per month. The amendment rectifies a typographical error in the original notice.